Skip to main content

Board of directors

 

Peter Wolpert

Executive Chairman and founder, M.Sc. Eng., M.Sc. Econ.

Born 1969. Active in the company since 2006. CEO and founder, Master degrees from Royal Institute of Technology, Stockholm and from Stockholm School of Economics, Stockholm.  Peter Wolpert has more than 20 years of experience as CEO, strategy consultant and entrepreneur and is a board member of MedUniverse AB. He was co-founder of Ibility AB and previously held positions as CEO of Athera Biotechnologies AB and strategy consultant at McKinsey & Co.

Shareholding: 435 399 shares through Wolco Invest AB and 130 000 employee stock options (130 000 shares may be subscribed to, based on the employee stock options).

 

Fredrik Granström

Born 1968. Member since 2019. Fredrik Granström is an attorney at law and partner with Hansen Advokatbyrå. Fredrik has been Moberg Pharma’s legal advisor since the company was founded 2006. Fredrik has more than 20 years’ experience as advisor, entrepreneur and corporate counsel for clients in the life science and tech industry. He has amongst other previously held positions as corporate counsel at AstraZeneca, Sendit AB, Microsoft Corporation and as chairman of the board of Soundtrap AB.

Shareholding: 0 shares. Independent in relation to the company and the owners.
 
 
 

Mattias Klintemar

Born 1967. Member since 2015. Mattias Klintemar represents Östersjöstiftelsen and has extensive experiences from leadership roles within the finance and technology sector, e.g.as CEO at Morphic Technologies AB, CFO at Hexaformer and senior corporate finance associate at ABG Sundal Collier and auditor at Arthur Andersen. He is Chairman of the board at Dilafor ad a board member at Oatly, Phoniro and Axelar as well as chairman of the nomination committee of Lightlab, Pharmanest and Cellimpact.

Shareholdin: 7 000 shares. Independent in relation to the company.

Andrew B. Hochman

Born 1979. Member since 2019. Andrew B. Hochman has over 16 years of experience in investments in pharmaceutical and consumer health care and is currently a partner at RoundTable Healthcare Partners, where he is involved in all parts of the transaction process, including deal sourcing, transaction structuring, valuation, due diligence, negotiations, financing and business strategy implementation. He joined RoundTable in 2007 from Graceway Pharmaceuticals, where he worked as Vice President of Business Development, and before that he was an associate at GTCR Golder Rauner and an analyst at William Blair & Company. He holds a Bachelor of Science degree in economics from Wharton School and a Bachelor of Arts in Psychology from the University of Pennsylvania. He is a board member of Santa Cruz Nutritionals, Revision Skincare / Goodier Cosmetics, Deerland Probiotics & Enzymes and Advantice Health, and has previously been a board member of Aqua Pharmaceuticals.

Shareholdin: 0 shares. Independent in relation to the company.

 

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.